ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with Avastin® and Carboplatin in Ovarian Cancer
ImmunoGen, Inc. (IMGN)
Last immunogen, inc. earnings: 5/1 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.immunogen.com/investor-relations
Company Research
Source: Business Wire
Data from Avastin Cohort to be Presented at 2018 ASCO Annual Meeting Updated Data from Carboplatin Dose-Escalation Cohort Demonstrate Increased Response Rate and Durable Benefit with Longer-Term Follow Up Conference Call Scheduled for 8 a.m. ET on Thursday, May 17 WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer today announced positive data from the FORWARD II trial evaluating mirvetuximab soravtansine in multiple combination cohorts in patients with folate receptor alpha (FRa)-positive ovarian cancer. Results from the cohort assessing mirvetuximab in combination with Avastin (bevacizumab) in patients with platinum-resistant disease will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 1-5 in Chicago, IL. In ad
Show less
Read more
Impact Snapshot
Event Time:
IMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMGN alerts
High impacting ImmunoGen, Inc. news events
Weekly update
A roundup of the hottest topics
IMGN
News
- Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Immunogen Inc SVP & CHIEF BUSINESS OFFICER Stacy Coen Sells 4,583 Shares [Yahoo! Finance]Yahoo! Finance
- ImmunoGen, Inc. (NASDAQ: IMGN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- AbbVie Sees Signs of Post-Humira Growth in Positive 2024 Outlook [BNN Bloomberg (Canada)]BNN Bloomberg
- ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
IMGN
Earnings
- 11/2/23 - Beat
IMGN
Sec Filings
- 2/12/24 - Form 4
- 2/12/24 - Form 4
- 2/12/24 - Form 4
- IMGN's page on the SEC website